Supplementary Data1 from CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib

Hans Gelderblom; Albiruni Abdul Razak; Matthew H. Taylor; Todd M. Bauer; Breelyn A. Wilky; Javier Martín‐Broto; Alejandro Falcón; Piotr Rutkowski; Bartłomiej Szostakowski; Thierry Alcindor; Ramy Saleh; Sofia Genta; Silvia Stacchiotti; Michiel A. J. van de Sande; Andrew J. Wagner; Nicholas M. Bernthal; Lara E. Davis; Jacqueline Vuky; Christopher Tait; Bahar Matin; Supraja Narasimhan; Maitreyi G. Sharma; Rodrigo Ruiz‐Soto; Matthew L. Sherman; William D. Tap

doi:10.1158/1078-0432.27013703

Abstract

Supplement to CSF1R Inhibition in Patients With Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase 1 Study of Vimseltinib. Contains supplementary methods, tables, and figures.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gelderblom et al. (2024) studied this question.

synapsesocial.com/papers/68e58a5ab6db6435875263f4 https://doi.org/10.1158/1078-0432.27013703

View at Publisher

Ask AI

Bookmark

Share

Supplementary Data1 from CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib

Abstract

Discussion

Cite This Study

Supplementary Data1 from CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers